Authors
Latest:
Dr. Factor on the Lack of Standardization in Biomarker Testing in Breast and GI CancersRachel E. Factor, MD, MS, discusses the lack of standardization with biomarker testing in breast and gastrointestinal cancers.
Latest:
Dr Holowatyj on the Potential Role of Germline Genetic Features in Appendiceal Cancer SusceptibilityAndreana N. Holowatyj, PhD, MSCI, discusses results from an investigation of germline genetic features that may confer cancer susceptibility in patients with appendiceal cancer.
Latest:
Unmet Needs in the Management of Advanced RCCDrs Alter and Diamond muse about the unmet needs in advanced RCC treatment.
Latest:
Dr Allan on the Importance of BTK Inhibitors and BCL2 Inhibitors in CLLJohn N. Allan, MD, discusses the importance of understanding fixed-duration treatment approaches with BTK inhibitors and BCL2 inhibitors in patients with chronic lymphocytic leukemia, highlighting data within this treatment armamentarium.
Latest:
Dr. Bhalla on Unmet Needs in the Treatment of EGFR Exon 20–Mutant NSCLCSheena Bhalla, MD, discusses the need for improved understanding of EGFR exon 20 insertion mutations in the development of non–small cell lung cancer treatment.
Latest:
Rapid Readout: Routine Clinical Practice Use of IRd in Patients With Relapsed/Refractory Multiple Myeloma (The INSURE Study)Expert perspective on the INSURE study, which pooled data from several trials to observe the real-world effectiveness of IRd in the setting of relapsed/refractory multiple myeloma.
Latest:
Dr. Das on the Results of a Clinical Score Analysis in Patients With NETsSatya Das, MD, MSCI, discusses the results of a clinical score analysis in patients with neuroendocrine tumors.
Latest:
Dr Wermke on the Investigation of BI 764532 in DLL3+ SCLC and NECMartin Wermke, MD, discusses the investigation of BI 764532 in patients with DLL3-positive small cell lung cancer and neuroendocrine carcinoma.
Latest:
Dr. de Marinis on the PERLA Trial in Metastatic NSCLCFilippo de Marinis, MD, discusses the goal of the phase 2 PERLA trial in metastatic nonsquamous non–small cell lung cancer, as well as significant results from a primary analysis of this study.
Latest:
Superagonists Pull IL-15 Into Focus in Oncology CareFollowing in the footsteps of the cytokine interleukin-2, IL-15 affords investigators similar qualities as a target without the associated toxicities of its immunotherapeutic predecessor.
Latest:
Dr Bertaina on T-allo10 Infusion in Young Patients With Hematologic MalignanciesAlice Bertaina MD, PhD, discusses T-allo10 infusion post–aβdepleted-HSCT in young patients with hematologic malignancies.
Latest:
Women in Oncology: Lessons to Tell Up-and-Coming Female OncologistsLaura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, provide advice to female oncologists who are just starting out their careers.
Latest:
Anticipating Key Studies and Pipeline Treatments in mCRC LandscapeThe experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.
Latest:
Dr Llanos on Prediagnositic Allostatic Load and Breast Cancer Clinicopathology in Black WomenAdana A.M. Llanos, PhD, MPH, discusses the relationship between prediagnostic allostatic load and breast cancer clinicopathology in Black women.
Latest:
Drs El-Khoueiry and Hughes-Halbert on the Importance of a Multidisciplinary Approach in Cancer CareAnthony B. El-Khoueiry, MD, and Chanita Hughes-Halbert, PhD, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.
Latest:
Biomarker Testing Challenges in HER2-mutated NSCLCExperts on HER2 non–small cell lung cancer provide clinical insights on biomarker testing challenges and the role of reflex testing.
Latest:
Advice For Providers Caring for Patients With HR+/HER2- mBCVirginia Kaklamani, MD, and Elizabeth Diaz, PA-C, share advice for providers managing patients with HR+/HER2- metastatic breast cancer.
Latest:
Dr. Barzi on the Need for More Sensitive MRD Testing in CRCAfsaneh Barzi, MD, PhD, discusses the need for more sensitive minimal residual disease testing in colorectal cancer.
Latest:
Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic CancerA phase 1/2 study will assess the safety and efficacy of azeliragon in patients refractory to first-line treatment of metastatic pancreatic cancer.
Latest:
Fellows on Film: How To Market Yourself for a FellowshipRichard J. Bleicher, MD, FACS, and Salvatore Nardello, DO, discuss how to market oneself for a fellowship in oncology.
Latest:
Dr. Till on Data With Liso-Cel Vs Other Products Under Examination in MCLBrian Till, MD, discusses the safety and efficacy of lisocabtagene maraleucel compared with other products under exploration in patients with mantle cell lymphoma.
Latest:
Choosing Your PathMegan M. Dupuis, MD, shares the complex journey she traveled during medical training and how it brought her to the academic setting.
Latest:
Dr Hillengass on the Rationale For Investigating the Effect of Exercise on Functional Performance in Multiple MyelomaJens Hillengass, MD, PhD, discusses the rationale for investigating exercise and its effect on functional performance in multiple myeloma, and highlights the methods utilized in this study.
Latest:
Dr. Shallis on the Investigation of Uproleselan in AMLRory Shallis, MD, discusses the investigation of uproleselan in acute myeloid leukemia.
Latest:
Targeting Transcription as a New Frontier in Advanced Pancreatic CancerA new focus of research has reconsidered the mechanisms in regulating transcription as a novel target for advanced pancreatic ductal adenocarcinoma.
Latest:
Dr. Baljevic on the Current Limitations of CAR T-Cell Therapy in Multiple MyelomaMuhamed Baljevic, MD, discusses the current limitations of CAR T-cell therapy in multiple myeloma.
Latest:
Dr. Halperin on the Efficacy of the Protocol PEN-221-001 Study in Advanced GI NETsDaniel M. Halperin, MD, discusses the efficacy and safety results of the phase 1/2a Protocol PEN-221-001 trial in advanced gastrointestinal mid-gut neuroendocrine tumors.
Latest:
Oncology Fellows Derive the Greatest Benefit From Advanced Research TrainingAimed at growing the translational workforce, most hubs offer different accelerated advanced degree opportunities to oncology trainees, such as master’s degrees in clinical and/or translational research, or graduate certificates.
Latest:
A Gut Check on the Digital Divide: How Wearable Devices Are Changing Cancer CareThe idea to provide wearable devices to my patients first came to me 6 years ago at a charity spinning event.
